Showing results (41-50 of 64) with videos related to
Sort By:
Pageof 7
International Journal of Cardiology|May 27, 2018
High bleeding risk patients with acute coronary syndromes treated with contemporary drug-eluting stents and Clopidogrel or Ticagrelor: Insights from CHANGE DAPTPaolo Zocca, Marlies M Kok, Liefke C van der Heijden, et al.Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|October 19, 2019
Three-year clinical outcome in all-comers with "silent" diabetes, prediabetes, or normoglycemia, treated with contemporary coronary drug-eluting stents: From the BIO-RESORT Silent Diabetes studyEline H Ploumen, Rosaly A Buiten, Marlies M Kok, et al.Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|March 4, 2014
Complex patients treated with zotarolimus-eluting resolute and everolimus-eluting Xience V stents in the randomized TWENTE trial: comparison of 2-year clinical outcomeHanim Sen, Ming Kai Lam, Kenneth Tandjung, et al.Journal of Cardiology|August 2, 2016
Two-year outcome after treatment of severely calcified lesions with newer-generation drug-eluting stents in acute coronary syndromes: A patient-level pooled analysis from TWENTE and DUTCH PEERSJennifer Huisman, Liefke C van der Heijden, Marlies M Kok, et al.Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|March 8, 2014
Coronary artery dominance and the risk of adverse clinical events following percutaneous coronary intervention: insights from the prospective, randomised TWENTE trialMing Kai Lam, Kenneth Tandjung, Hanim Sen, et al.Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|November 21, 2017
Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPTPaolo Zocca, Liefke C van der Heijden, Marlies M Kok, et al.Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|January 30, 2013
Women treated with second-generation zotarolimus-eluting resolute stents and everolimus-eluting xience V stents: insights from the gender-stratified, randomized, controlled TWENTE trialKenneth Tandjung, Mounir W Z Basalus, Hanim Sen, et al.Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|May 15, 2012
Comparison of eligible non-enrolled patients and the randomised TWENTE trial population treated with Resolute and Xience V drug-eluting stentsHanim Sen, Kenneth Tandjung, Mounir W Z Basalus, et al.Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation|August 24, 2010
TWENTE Study: The Real-World Endeavor Resolute Versus Xience V Drug-Eluting Stent Study in Twente: study design, rationale and objectivesM W Z Basalus, K Tandjung, K G van Houwelingen, et al.The American Journal of Cardiology|September 4, 2012
Comparison of frequency of periprocedural myocardial infarction in patients with and without diabetes mellitus to those with previously unknown but elevated glycated hemoglobin levels (from the TWENTE Trial)Kenneth Tandjung, K Gert van Houwelingen, Hanneke Jansen, et al.Pageof 7